Absolutely. The whole “startups fail” argument is nonsense and...

First 14606 Last

Share
Profile

Follow
Kuade

136 Posts.

28

30/06/21

12:39

Post #: 54173571
Share

Originally posted by Fact Finder: ↑

One interesting thing about the statistics thrown around about 97% and 9 out of 10 start-ups failing is that the numbers giving rise to these figures include believe it or not small businesses such as hairdressers, coffee shops, first year out carpenters as well as ASX listed start-ups. So they are flawed statistics the only value of which is to allow for sensational journalism and grubby down ramping.

In 2016 the ASX commissioned a report as to how it might reduce the failure rate of ASX start-ups and the primary recommendation was that lack of sufficient funding at the time of listing was the dominant problem as the majority of the failed companies listed with only $2 to $3 million dollars in capital and it was recommended that a listing requirement that an applicant company have capital reserves of at least $10 million at time of listing would substantially reduce the risk of failure.

This recommendation was clearly thought by those who carried out the research for the ASX to be sufficient to dramatically reduce the failure rate.

The continued absolute rubbish about start-ups failing 90% of the time has no merit to a consideration of a company like Brainchip with significant current capital reserves, a product in the market place and a contractual right to call on LDA Capital for up to $20 million additional dollars and income from an international company that has already licenced its product.

I cannot believe that this rubbish is still being thrown around.

My opinion only DYOR
FF

AKIDA Balliista

Expand

Absolutely. The whole “startups fail” argument is nonsense and totally irrelevant when it comes to BRN.

BRN Price at posting: 48.0¢ Sentiment: Buy Disclosure: Held
10 Upvote

1 Great analysis

Reply

Top Stories

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

PL3

Patagonia looks to raise $2.15M for South American exploration and development

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

There are more pages in this discussion • 18,975 more messages in this thread...

First 14606 Last

Add BRN (ASX) to my watchlist

(20min delay)
Last 20.0¢		Change -0.005(2.44%)		Mkt cap ! $371.1M

Open	High	Low	Value	Volume
21.0¢	21.0¢	19.5¢	$1.251M	6.200M

Buyers (Bids)

No.	Vol.	Price($)
42	1837538	19.5¢

Sellers (Offers)

Price($)	Vol.	No.
20.0¢	114606	3

View Market Depth

No.	Vol.	Price($)
42	1837538	0.195
61	1919811	0.190
26	1199558	0.185
47	1495778	0.180
11	490041	0.175

Price($)	Vol.	No.
0.200	114606	3
0.205	808754	10
0.210	437793	13
0.215	384760	13
0.220	785250	21

Last trade - 16.10pm 09/07/2024 (20 minute delay)

BRN (ASX) Chart

Absolutely. The whole “startups fail” argument is nonsense and...

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Patagonia looks to raise $2.15M for South American exploration and development

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Absolutely. The whole “startups fail” argument is nonsense and...

Top Stories

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Patagonia looks to raise $2.15M for South American exploration and development

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News